- All
- Conferences
- Research
DDL Conference 11 – 13 December Edinburgh
The Drug Delivery to the Lungs (DDL) Conference provides an annual forum for scientists, academics, clinicians, regulatory and industry specialists involved in developing medicines for inhalation. Fluidda is actively involved in… View Article
The effects of particle size in deposition projects – ERS 2019
During the ERS 2019 two posters were presented on the deposition of extrafine vs. non-extrafine formulations of different respiratory drugs in different inhalation devices. Both studies were conducted with Functional… View Article
How does FRI compare to spirometry?
Functional Respiratory Imaging (FRI) parameters can reduce the number of patients required in clinical trials up to sixteen times compared with spirometry while maintaining adequate power and statistical significance. FRI… View Article
The value of Fluidda in respiratory clinical research – ERS 2019
Prof. W. De Backer, Chairman of the Board of Fluidda nv, was interviewed at the ERS 2019 conference in Madrid about the insights that lead to the founding of the… View Article
The advantages of using FRI in clinical trials – ERS 2019
Glenn Leemans, Fluidda’s Chief Operative Officer (COO), was interviewed at the ERS 2019 conference in Madrid. In this interview, Glenn explains why Fluidda’s proprietary functional respiratory imaging (FRI) technique can… View Article
RSNA 2019 – Annual Congress 1st – 6th December Chicago
Fluidda will be present at the annual congress of the Radiological Society of North America (RSNA). This year’s congress will take place during 1-6 December in Chicago, Illinois . The RSNA… View Article
Using FRI to detect early wildfire exposure on lung development
During the ERS 2019 conference, Fluidda presented the results of a study which investigated that FRI (Functional Respiratory Imaging) parameters can be a sensitive tool to detect early-life wildfire smoke… View Article
Understanding Mucus in Chronic Obstructive Pulmonary Disease (COPD)
Mucus plays a major role in Chronic Obstructive Pulmonary Disease (COPD), especially in the Chronic Bronchitis phenotypes. Mucus increases airway resistance making it harder for the patient to breath. At… View Article
The highlights of ERS 2019 by Jan De Backer, CEO of Fluidda
At ERS 2019, Jan de Backer, CEO of Fluidda, explains why during the past years, the treatment of lung diseases is shifting from using more common bronchodilatators to more personalized… View Article
ERS 2019 – We are present with our booth and 7 posters
From September 28 until October 2, Fluidda will exhibit at the annual conference of the European Respiratory Society (ERS) in Madrid, Spain. During this conference, Fluidda will present 7 posters on… View Article